公开(公告)号：US20210371394A1

公开(公告)日：2021-12-02

申请号：US17322409

申请日：2021-05-17

Applicant: Novartis AG

Inventor： Zichen JIA ,  Philipp LUSTENBERGER ,  Marie MEYER ,  Massimo MORATTO

IPC: C07D401/06

Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.

公开(公告)号：US20230265067A1

公开(公告)日：2023-08-24

申请号：US18168711

申请日：2023-02-14

Applicant: Novartis AG

Inventor： Zichen JIA ,  Philipp LUSTENBERGER ,  Marie MEYER ,  Massimo MORATTO

IPC: C07D401/06

CPC classification number: C07D401/06 ,  C07B2200/13

Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.